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Abstract
Background: Women from families with a high risk of breast or ovarian cancer in which genetic testing for
mutations in the BRCA1/2 genes is inconclusive are a vulnerable and understudied group. Furthermore, there are
no studies of the professional specialists who treat them - geneticists, genetic counsellors/nurses, oncologists,
gynaecologists and breast surgeons.
Methods: We conducted a small qualitative study that investigated women who had developed breast cancer
under the age of 45 and who had an inconclusive BRCA1/2 genetic diagnostic test (where no mutations or
unclassified variants were identified). We arranged three focus groups for affected women and their close female
relatives - 13 women took part. We also interviewed 12 health professionals who were involved in the care of
these women.
Results: The majority of the women had a good grasp of the meaning of their own or a family member’s
inconclusive result, but a few indicated some misunderstanding. Most of the women in this study underwent the
test for the benefit of others in the family and none mentioned that they were having the test purely for
themselves. A difficult issue for sisters of affected women was whether or not to undertake prophylactic breast
surgery. The professionals were sensitive to the difficulties in explaining an inconclusive result. Some felt frustrated
that technology had not as yet provided them with a better tool for prediction of risk.
Conclusions: Some of the women were left with the dilemma of what decision to make regarding medical
management of their cancer risk. For the most part, the professionals believed that the women should be
supported in whatever management decisions they considered best, provided these decisions were based on a
complete and accurate understanding of the genetic test that had taken place in the family.
Background
In an investigation of psychosocial aspects of genetic
counselling and testing, Vadaparampil et al (2004) con-
cluded that a key area deserving research and clinical
attention was the area of inconclusive test results [1].
Members of hereditary breast/ovarian cancer (HBOC)
families who have been affected by cancer are offered
testing for mutations in the BRCA1 and BRCA2 cancer
predisposition genes with the hope of identifying the
cause of the family’s cancers. This can then provide
information for others in the family about their own
individual risk. In the majority of cases, no pathogenic
mutation is identified [2]. This may mean that the tested
family member developed cancer by chance, or there is
a very small chance that a mutation is present in
BRCA1 or BRCA2 but was missed due to limitations in
current technology. Alternatively, the individual may
have a mutation in a gene, or genes yet to be identified.
Currently, genetic testing does provide information on
variants of unknown significance (VUS). However, in
our small study, no variants had been detected on our
group of tested breast cancer patients.
The fact that there is no identified pathogenic muta-
tion in a BRCA genetic test may pose problems for the
woman and the provider. Both may need to make deci-
sions based on uncertain information. For example, it is
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mutation in the BRCA1 gene may have different tumour
characteristics, different recurrence risks and possibly
different treatment implications [3-6]. One of the rea-
sons that women disclose their positive BRCA genetic
test result is to provide genetic risk information to their
sisters or daughters. But in the case of an inconclusive
result, they can only rely on their family history, and
have no genetic test to offer their kin. How does this
make the woman feel? There is limited information that
focuses specifically on women receiving an inconclusive
genetic test result [2,7,8].
Patenaude et al [9] and Gadzicki and Wingen [10]
found that women with inconclusive results reported
their results less frequently to their relatives than did
women with a positive result [1,10]. Furthermore, even
though a large majority of tested women told their sis-
ters their genetic results, fewer did so when the results
were inconclusive [9,11]. Research findings have dif-
fered with respect to the implications of receiving an
inconclusive result. Those who received an inconclu-
sive, rather than a positive result, said that they were
more worried about cancer, less relieved by their test
result and felt that their quality of life had been more
adversely affected by it [12]. Another study concluded
that women with a high familial risk but with no iden-
tified mutation appeared to be reassured after disclo-
sure and showed the same levels of worry and distress
after genetic testing as did women who were identified
as BRCA carriers [2]. Yet, O’N e i l le ta l[ 8 ]f o u n dt h a t
women who had an intolerance of uncertainty were at
risk for long-term distress. Maheu and Thorne [13]
reported the effect of uninformative BRCA results in
another small qualitative study. Women made sense of
their test results by drawing on their own understand-
ing of the patterns of breast and ovarian cancer that
was in their families and subjectively assumed that
they were either carriers or not. Another study looking
at the long term effect of BRCA genetic testing on
women noted that the majority of 147 women with
inconclusive genetic test results were relieved not to
be identified as a mutation carrier, although this relief
was not as great as that felt by women receiving a true
negative predictive test result [14]. More recently,
Cypowyj et al [15] found that the majority of women
with inconclusive results felt unsure as to what this
result really meant.
We could not find any peer-reviewed articles on the
investigation of the roles of health-care professionals
who interact with women facing the uncertainty inher-
ent in an inconclusive genetic test result. One study
that does look at the role of the professional with
regard to advising women with known BRCA muta-
tions about preventive surgery [16] suggests that BRCA
carriers also have dilemmas related to decision making
about different prevention options, though, more is
known about their future risk. Another related article
by Matloff et al [17] examined what cancer genetics
specialists predicted that they would do themselves if
they were at 50% risk of carrying a BRCA1 or BRCA2
mutation. To the best of our knowledge, ours is the
first study to investigate the experience of both the cli-
ents from a cancer genetic risk clinic and the profes-
sional providers that treat them within the same
institutional social context.
Methodology
We conducted a qualitative exploratory study at a major
cancer centre in the UK. A qualitative research design
was chosen because of its ability to capture complexity
and process and the meaning attached to individual
action [18]. The researchers used an inductive process
involving coding and identification of recurrent patterns,
relationships and processes in the data, which empha-
sises the participants’ own accounts of their phenomen-
ological and social world [19-21]. This approach does
not assume that there is only one measure of reality
that can be objectively grounded [22,23]. We used both
individual interviews and focus groups to gather as
much rich data as possible. The most important feature
of focus groups is the ability to gather in-depth
responses as part of the interaction between the group
participants [24,25].
We chose focus groups as the methodology for the
women because we knew from clinical experience that
the topic was an emotional one and that the interactions
between the women ought to reveal richer information
than could be gathered through individual interviews.
Any differences between the interviews of the profes-
sionals and the focus groups should be minimal because
focus groups are group interviews [26]. The focus group
and individual interview guides were similar in that both
asked general questions, followed by probes on topics of
interest described below and thus the findings can be
compared.
Focus Groups
Letters of invitation were sent to 16 women who had
undergone BRCA1 and BRCA2 mutation analysis
through a cancer genetics clinic at a major cancer centre
in the UK. All these women had received written notifi-
cation informing them of their “inconclusive” genetic
test result. All had experienced a diagnosis of breast
cancer under the age of 45, and had a living daughter
and/or a sister without cancer over the age of 18. We
offered the women a choice of three dates. Two women
brought one sister to the focus group, one woman
brought two sisters and one woman brought a daughter.
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included women from different families. Four women
contacted us to say that they were unable to attend on
the dates proposed. The other four did not respond
even though we attempted to re-contact them by tele-
phone. If an individual was known to be currently
unwell and receiving treatment, they were not
approached. All the women signed informed consent
forms.
Because of the importance of this subgroup of women
from HBOC families and their health-care professionals
who care for them, we investigated reactions to incon-
clusive BRCA1/2 test results in both women from high-
risk families and professionals who practice in a large
cancer centre. We examined several issues: 1) how
women from these types of high-risk families who have
developed breast cancer under the age of 45 cope with
the uncertainty of developing a second primary breast
or ovarian cancer in the future; 2) how their female rela-
tives interpret and use these inconclusive results; 3)
whether this group are treated differently by health pro-
fessionals (as compared with those without a family his-
tory or those definitively shown to carry a BRCA1 or
BRCA2 mutation) in terms of surveillance advice and
recommendations for prophylactic surgery; and 4) health
professionals’ feelings about delivering inconclusive
genetic test results and issues in counselling these
women and whether this uncertainty affects the patient
doctor relationship.
We used a semi-structured moderator’sg u i d ew i t h
open-ended questions. Questions and probes were asked
relating to: dealing with uncertainty; regrets (if any)
about being tested for a genetic mutation; how relation-
ships and expectations have changed since their cancer
diagnosis; the effect of the passage of time; belief in
science and technology; attitudes towards health care
professionals; and family feelings about inconclusive
results.
Interviews with health care professionals
The 14 professionals at the cancer centre who worked
with women affected by, or at high familial risk of,
breast and ovarian cancer were invited by letter to parti-
cipate in the study. Only two refused, stating time con-
straints. We therefore interviewed 12 professionals
including staff from the following specialties: clinical
genetics, oncology, cancer genetic nurse counselling,
genetic counselling, gynaecological surgery and breast
surgery. The interviews, lasting from 15 to 30 minutes,
were conducted in the cancer centre.
Our purpose was to ascertain the professionals’ per-
spectives on health behaviours and prophylactic mea-
sures and their experiences with women in this
situation, including their perceptions of the women’s
attitudes and feelings as well as their own feelings. All
the professionals provided written informed consent.
We used an open-ended, semi-structured interview
schedule and asked specific questions about: the profes-
sionals’ experiences with women who had an inconclu-
sive BRCA1 and BRCA2 genetic test result; how they
dealt with the uncertainty raised by an inconclusive
result; their medical management advice for these
women and the reasoning behind the advice; whether
they believed that the women understood what an
inconclusive result was and how they endeavoured to
ensure accurate comprehension; whether they thought
there was disagreement among different specialists
about the medical management of these women; and
the professionals’ own emotional reaction to providing
an inconclusive result.
RK, EL, and AAJ analysed transcripts of the focus group
sessions and interviews for recurring themes after repeated
close reading of the material. They separately read and
reread the focus group and interview transcripts, noted
each theme presented by the respondents and then com-
pared and discussed their interpretations. There was close
agreement on the main themes. Direct quotes are used
throughout the paper to validate the findings. The focus
groups and interviews were tape-recorded with consent
from all the participants and the recordings were tran-
scribed. Only pseudonyms were used. The Hospital’sC l i n -
ical Research Committee and Local Regional Ethics
Committee approved the study. The authors confirm that
there is no conflict of interest between themselves and
others that might bias their work.
Findings: Participants
Several themes emerged from the focus groups. We dis-
cuss the main ones in more detail below.
Genetic Testing for the Benefit of Family Members
Most of the women in this study underwent the test for
the benefit of others in the family and none mentioned
that they were having the test purely for themselves. In
fact, four of the eight affected women said that they
would not have had the test at all if they did not feel
that it could provide helpful information for other rela-
tives, particularly sisters, daughters or nieces.
“I did this for the future generations. I wasn’t worried
about...the knock-on effect of me, I was already there.”
(Caroline, affected by cancer)
Implications of the Inconclusive Results
While the women seemed to accept the inconclusive
result as leaving them, as one woman put it, “back to
square one”, many of them were not sure how to
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standing at some level. Julie said that it was “sort of
good news”, but added, “isn’ti t ,It h i n k ”. Caroline dee-
ply believed that her cancer was caused by a genetic
mutation, but hoped that a positive genetic test might
lead to prevention of any further mutation, a scientifi-
cally flawed assessment. As indicated in the following
quote, Monica also misapprehended her situation.
“... of all the genes that one could pick up I’d far rather
it was breast cancer than so many other things which
are really, really so much more horrendous and difficult
to deal with. Because I think, you know, it’s quite a gen-
tle gene...”
(Monica, affected by cancer)
Management of Cancer Risk
T h em a j o r i t yo ft h ew o m e nf e l tt h a ta ni n c o n c l u s i v e
result allowed them to avoid making a choice about pro-
phylactic surgery, something they might have considered
more strongly if a mutation had been identified.
“I know it’s harder for my sister to make a decision....as I
said, I’d sort of made my mind up anyway, that it was
inherited, so whether it came back as positive, then it
would have made a difference for my sister who would’ve,
I think, probably gone down the line of having a prophy-
lactic mastectomy if it had definitely been positive now.”
(Mary, affected by cancer, referring to sister not
present)
Communicating inconclusive genetic test results
Telling adults
It is usual practice for a letter to be given to an indivi-
dual who carries a gene mutation to distribute to other
relatives informing them about the meaning of the test
result, the screening recommendations and how to
arrange referral to the clinic. It is not as common to
provide written information for family members of
those receiving inconclusive results. The women usually
did not tell relatives outside the immediate family about
their inconclusive BRCA1/2 mutation test result. They
felt that an inconclusive test result did not provide any
further information and might worry them unnecessa-
rily. A few of the women had particular difficulty in tell-
ing their mothers. Kim reported that her mother always
changed the subject so she did not press her, while
Monica tried to protect her mother.
“I think past a certain point it’s very complicated for...
for older people ...there’s a feeling of guilt there. ...I think
there’s no point in clouding their lives, really. I mean my
mother’s just had a stroke, I wouldn’t dream of mention-
ing to her that we’re here discussing a gene that may
have been passed on. I cannot see the point, I think it’sa
perfectly negative, unkind thing to do.”
(Monica, affected with cancer)
Telling Children
Some participants felt that there was no need to tell their
children about inconclusive results. They said, however,
that if a BRCA1 or BRCA2 mutation had been detected,
they would have told their children. It appears from the
quotes above and below that many of the women felt
that an inconclusive result gave them a reprieve from
having to be the bearer of bad news to the family.
“I think they [the older children] presumed that if it
was positive I would say something. And because I
haven’t said anything, it’s either negative or it’s inconclu-
sive. And I did say there was a high chance it would be
inconclusive.”
(Pat, affected by cancer)
Findings: Professionals
Understanding and explaining inconclusive genetic test
results
Geneticists, oncologists and genetic nurses/counsellors
are the health professionals that most often discuss risk
with women from families with a hereditary cancer diag-
nosis. They frequently find that the women they meet
with do not have a clear grasp of what an inconclusive
genetic test result means despite undergoing genetic
counselling prior to having testing, as well as receiving a
letter following an appointment.
“I think it’s one of the most difficult situations that you
have. So I think sometimes an uninformative result can
be associated with...anxiety on the part of the patient
and also on the part of the doctor, because we like to
deal with absolutes and I’m not sure that the medical
profession’s always very good at dealing with
uncertainty.”
(Dr D, oncologist)
The surgeons were more concerned that the women
were educated about their general cancer risk and risks
related to surgery.
.... there’s much that is unknown about this, and there-
fore we come back to making individualised decision-
making on the basis of the knowledge of the present
tumour, the risk-benefits of risk-reduction surgery against
the background of dying of breast cancer.
(Dr J, Breast surgeon)
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test results
Bilateral prophylactic mastectomy has been found to
reduce the risk of a future breast cancer for a woman
carrying a BRCA1 or BRCA2 mutation by as much as
90% [27]. The question of prophylactic surgery, how-
ever, becomes much more problematic in high-risk
women who have an inconclusive result. The profes-
sionals worry about the timing of surgery or that the
w o m e nm i g h tl e a r ni nf u t u r e ,b e c a u s eo fp r o g r e s sw i t h
testing technology that they do not, in fact, carry a
mutation and therefore had unnecessary surgery. But
some women who had seen most female members of
their families develop breast cancer wanted the proce-
dure, regardless of the test results, for peace of mind. Dr
H, a surgeon, was particularly worried about these
women.
“Id o n ’t think prophylactic surgery is for everybody...
although if you’ve definitely got the gene then fair
enough, you know, you can give them statistics, but to do
it on an inconclusive test, I really think it’s putting them
at risk of major psychological problems.”
(Dr H, breast surgeon)
The professionals also felt uncomfortable about a
woman choosing prophylactic surgery in the case of an
inconclusive result unless the family history was extre-
mely severe.
“There are some women who are absolutely adamant
that they want radical surgery immediately when they
have an inconclusive results and I would very much err
on the side of caution. There are, however, some women
who, with a really horrible family history where their
risk is obviously very great, who will not consider surgery
in any circumstance, where my own view might be that I
would encourage them to do so. Obviously in genetic
counselling we are totally nondirective but I think inevi-
tably your own sort of feelings and your own point of
view come through to a certain extent, I think it’s foolish
to try and sort of, um, say that we don’t...”
(Dr A., geneticist)
Agreement between professional specialties
Opinions varied regarding whether there were differ-
ences in management advice between professional spe-
cialties. A few of the professionals believed that the
different training among specialists provided slightly dif-
ferent lenses to interpret the same finding. Dr B, an
oncologist, said that from his and other oncologists’
experiences, there were differences between geneticists,
oncologists and surgeons.
“.... and it’s interesting, actually, because I do think
some oncologists are more pro-prophylactic surgery than
some geneticists, that’s certainly been my experience. And
that may be because ...it’s been coloured by their experi-
ence of looking after young people with cancer.”
(Dr B, oncologist)
Emotional reactions to providing inconclusive genetic test
results
N i n eo ft h et w e l v ep r o f e s s i o n a l ss a i dt h a tt h e yf o u n d
discussing inconclusive genetic test results with women
at high risk for breast and ovarian cancer to be difficult.
They used many different words to discuss these feel-
ings. They reported that they felt “uneasy”, “frustrated”,
“anxious”, “stressed”, “inadequate” or “disappointed”
because science still had not developed at test that
could give the women a definitive result. One oncologist
reported that sometimes when he could not provide an
answer, it made him feel that he was a failure in some
way. These types of feelings were most strongly
expressed by the professionals working in the genetics
clinic whose job it was to provide and explain genetic
test results.
“...I think it makes you feel a little bit anxious, that it
shifts the power, sort of, in the relationship. You’re not
the person who has all the answers, you’re having to
start sentences with words like “well, we don’t know...we
don’t know exactly what this means for your family” or
“we can be less certain about the risks in your family”...
and you know sometimes I think it can make you feel
that you’re a failure in some way and that you can’t pro-
vide an answer.”
(Dr D, oncologist)
Discussion
Women from HBOC families who receive inconclusive
BRCA test results are in a unique situation; their man-
agement and psychological issues are different from
both women in the general population and women
who are known to carry a gene mutation. They may
also be identified with a VUS (variant of unknown sig-
nificance) that may in the future change with time.
They do, however, share with the women in families in
which a BRCA1 or BRCA2 mutation has been identi-
fied a fear of a new cancer and the overwhelming
experience that comes along with that cancer [28]. The
women in this study who had had testing and a diag-
nosis of breast cancer wanted genetic testing mainly
for the benefit of others in their family, but receiving
an inconclusive test result left them with little infor-
mation to impart.
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that an inconclusive genetic test relieved them of having
to choose between unpleasant options about their future
medical management. They also felt relieved of the
responsibility of sharing information with more distant
members of their families because they did not believe
that telling them about an inconclusive result would be
meaningful and might be worrisome. These results con-
flict with those of Cypowyj et al [15]. Some of the parti-
c i p a n t si nt h e i rs t u d yf e l ts u r et h e yw e r ec a r r i e r s .
Patenaude et al [9] also found that women who received
inconclusive results less frequently conveyed these
results to even their first-degree relatives. However, in a
small, cross-sectional descriptive study, Loescher et al
[29] found that women who had uninformative test
results were concerned about screening needs for family
members.
The affected women and their unaffected sisters/
daughter who participated in the focus groups were a
self-selected sample. Relationships between the affected
woman and the family member/s who attended were
evidently good enough for them to attend together. Sev-
eral authors have indicated the support that sisters can
provide [11]. In our focus groups, there was wide varia-
tion in sisters’ interpretations of an inconclusive genetic
test and feelings about what preventive measures might
be taken in the future, some placed more emphasis on
the lack of clarity in the results than others. The presen-
tation of test results can be confusing. Frost et al [30]
recommended that both patients and health profes-
sionals needed to ensure that they used a common
vocabulary because “uncertain” can refer to both results
or outcome. The variability we found reflects the varia-
bility found in the literature [2,7,12,31]. One of the rea-
sons for this variability might be due to individual
differences in risk perception [32].
The professionals were very open about their opinions,
perceptions and feelings. They felt that members of dif-
ferent specialties might view the women’s risk situation
differently due to difference in their training, the kinds
of patients they most commonly saw. The findings that
were the most interesting were those related to the pro-
fessionals’ emotional reaction to delivering inconclusive
genetic test results. The professionals appeared to worry
more about the interpretation of inconclusive results
than the women did about receiving them, and many of
the specialists found it difficult to feel assured that their
patients left the counselling session with an accurate
understanding of the meaning of an inconclusive result.
Feelings of stress, disappointment and anxiety were
expressed primarily by those working in the genetic
clinic whose task it was to present the inconclusive
results to the women. The breast surgeons, however,
were less affected as they tended to work from the
premise that the women had received sufficient and
accurate information from the genetics clinic.
The professionals also were not sure about how to
explain accurately what an inclusive genetic test result
meant to extended kin. Hallowell et al [33] found that
the women in her study required clear information
about the meaning and implications of the different
types of test results because some of them interpreted
an inconclusive result as definitive confirmation that a
cancer-predisposition mutation was not present within
the family. Dorval et al [12] concluded that it was
important for the health professionals to fully impart to
women that an inconclusive result does not preclude
the possibility that women in the families with an incon-
clusive genetic test may still be at a higher risk of devel-
oping breast and ovarian cancer.
Limitations
There are several limitations to this exploratory study.
Firstly, the sample is small. Also, all the participants
described their relationship with the relative who
attended as close; those who were not close may well
have responded differently. Furthermore, the study
location may be atypical because it is a major research
cancer centre rather than a district hospital. Women
who developed breast cancer and were treated in a dis-
trict hospital may not have had similar experiences
because of the differences in the location of genetic
services. It is a retrospective study and selective mem-
ory may act as a bias. Also, participation in a focus
group and hearing opinions of others may change indi-
vidual women’s perspectives and not reflect their opi-
nions prior to their participation. Members of focus
groups react to comments of other participants. Indivi-
dual interviews are conducted privately and while the
interviewees cannot be impacted by the opinions of
others, they also may forget to mention important atti-
tudes that might have been elicited through others’
statements.
Despite these limitations, we feel that the findings of
this study are important because it is the first study that
we are aware of that looks at both the health profes-
sionals’ and women’s cognitive and emotional perspec-
tives related to the receipt of an inconclusive BRCA1
and BRCA2 mutation detection test. This research also
provided ideas for improving follow-up care for these
women from HBOC families.
Suggestions for improved care
Based on the themes that emerged from this study, it
w o u l ds e e mt h a tt h en e e d so fw o m e nw h oh a v e
received inconclusive results are mostly, but not
always, met. Usual practice in this particular clinic is
for women with inconclusive results to receive their
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they wish to discuss the result further. Hallowell et al
[33] recommended that all persons who were informed
that they had an inconclusive genetic test result should
have a follow-up session with a genetic clinician either
by telephone or in person, although this may be lim-
ited by resources within a publicly-funded institution.
It maybe helpful to develop services such as study
days, specifically for women who have received uninfor-
mative BRCA test results such as study days. A newslet-
ter may be another option to update people who have
undergone genetic testing. Increasingly, health websites
have been a resource and support for women at high
risk. A major one is FORCE (Facing Our Risk of Cancer
Empowered) [34]. We would also suggest that easy-to-
read leaflets be designed that could be handed out to
extended kin with up-to-date scientific explanations on
genetic testing as well as management options and con-
tact numbers that could be accessed by both the families
and other health professionals. Annual telephone con-
tact could provide them with an update on new issues
relating to their family history and genetic testing status
e.g. new screening modalities for high risk women
where there is no identified mutation. Some of these
women may be being screened in an outreach clinic
where professionals are not immediately aware of new
developments in the genetics field.
Even though genetics professionals had a clear under-
standing of the scientific basis of an inconclusive BRCA
genetic test result, they expressed frustration when
imparting this information in light of the uncertainty
involved. Perhaps workshops addressing how to cope
with this frustration should be offered at professional
m e e t i n g s .I ti sa l s oi m p e r a t i v et op r o v i d eu p - t o - d a t e
genetic information to other health-care professionals.
These can be arranged as part of ‘update’ study days as
well as through written or web-based communication.
Clinicians at large institutions often benefit from prac-
ticing as part of an interdisciplinary team. Health profes-
sionals caring for women who have had an inconclusive
genetic test need to be updated continuously with
regard to new scientific discoveries; for example, in the
interpretation of tumour histology and its impact on the
probability of an association with a germline mutation
[4]. It is essential that formal or informal links between
geneticists and other professionals caring for these
patients be formed.
Conclusions
This study has highlighted the complex feelings of
women who find it hard to make decisions with regard
to the management of their own health in the face of
uncertainty, their fears for their own futures, as well as
their concerns for their families. Some of the members
of the medical teams who manage these HBOC families
who have received inconclusive BRCA test results also
experienced emotional difficulties and feelings of inade-
quacy and unease when discussing prevention options
due to state of current knowledge in the field. Institut-
i n gt h es u g g e s t i o n sm a d ea b o v em a yg oal o n gw a yi n
ensuring that women from HBOC families with an
inconclusive BRCA1 and BRCA2 mutation result receive
information about the latest scientific advances and
medical management options.
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